Balestrino, R;
Martone, T;
Toffoli, M;
Montanaro, E;
Fabbri, M;
Artusi, CA;
Romagnolo, A;
... Schapira, AHV; + view all
(2023)
Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.
Neurological Sciences
10.1007/s10072-023-07173-1.
(In press).
![[thumbnail of Schapira_manuscprit NEUS rev clean.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Schapira_manuscprit NEUS rev clean.pdf Access restricted to UCL open access staff until 7 November 2024. Download (144kB) |
Abstract
Background: Levodopa-carbidopa intestinal gel infusion (LCIG) is a therapeutic option for advanced Parkinson disease (PD) patients with troublesome motor complications, unresponsive to conventional oral treatment. There is some evidence to suggest that the genetic background may influence the clinical presentation and rate of progression of PD. Whether the genetic background influences the outcome of device-assisted therapies is currently debated. Some studies have investigated the effectiveness of deep brain stimulation (DBS) in PD patients with different genetic background, while evidence is lacking regarding LCIG. // Methods: A cohort of LCIG patients underwent genetic testing. The motor and neuropsychological outcomes of LCIG were retrospectively analyzed. // Results: Fifty-six patients were analyzed, nine of them (15%) had at least one mutation/variant in a PD-associated gene: five GBA1, two SNCA, one LRRK2, one PRKN; 13 (23%) carried the BDNF Val66Met polymorphism. The mean duration of follow-up was 4.9 ± 2.6 years. There were no significant differences in motor or neuropsychological outcomes between patients with and without these gene mutations/variants. No cognitive worsening was observed at follow-up among GBA-PD patients, and they responded well to LCIG in terms of motor symptoms. // Conclusions: Overall, we observed a significant benefit in terms of motor complications in our cohort, including patients carrying genetic mutations/variants. Due to the small sample and limited number of patients carrying genetic mutations/variants, no definitive conclusions can be drawn yet on the genotype impact on LCIG outcome. A careful selection of patients, regardless of the genetic background, is pivotal for an optimal outcome of LCIG.
Archive Staff Only
 |
View Item |
